BRUIN CLL-313 showed significantly longer progression-free survival vs bendamustine plus rituximab, bringing a noncovalent BTK inhibitor to first-line care.
|Articles|March 1, 2004
- Volume 0 0
Xenical
Advertisement
Roche (Nutley, NJ) recently announcedthat the FDA has approved labeling foruse of the prescription weight-loss medicationXenical (orlistat) in the managementof obese adolescents aged 12 to 16years. This approval offers physicians andparents of overweight and obese adolescentsa safe and effective treatment optionto help manage their weight. Xenicalworks locally in the stomach to preventdietary fat absorption by approximately30%. It helps the patient lose weight aswell as maintain the weight loss. For moreinformation, visit www.xenical.com.
Articles in this issue
over 22 years ago
Interface Speeds Up Prescription Fillingover 22 years ago
New Technologies Top Surveyover 22 years ago
Partnership Addresses Packaging Solutionsover 22 years ago
PDX Software Gets High Marksover 22 years ago
Polar Powder Cold Pak with Magnetic Therapyover 22 years ago
Seal•ONover 22 years ago
SaltAire Sinus Reliefover 22 years ago
Zim's Crack Creme Hand Sanitizerover 22 years ago
CoroWise Plant Sterolsover 22 years ago
CulturelleAdvertisement
Related to this article
A behavioral walking program matched supervised aerobic training for improving asthma control in a randomized trial of physically inactive adults.
Phase 2b data from EASD 2026 show the amylin-incretin combination also cut HbA1c by up to 2.9% in adults with obesity or overweight and type 2 diabetes.
American Pharmacists Month kicked off on October 1, honoring more than 700,000 pharmacy professionals and 250 years of caring for America's communities.
fMRI data show cagrilintide-semaglutide altered brain responses to high-calorie food cues; REIMAGINE analyses point to ectopic fat and bone effects.
Decades after cisplatin's approval, platinum-based chemotherapy continues to anchor treatment regimens across tumor types, new research finds.
A pharmacist-led collaborative drug therapy management program at NYC Health + Hospitals/Bellevue reported high patient satisfaction, and every surveyed patient said they felt respected and supported by their pharmacist.
A Novo Nordisk–funded claims analysis of adults with type 2 diabetes found an adjusted HR of 1.06 for MACE with switching, although the findings cannot show causation.
Advertisement
Advertisement